The media company has added managed-markets expertise to its roster, bringing on the former head of IMS Health's global payer/provider division.
Parent company CVS Caremark is changing its name to better reflect "its broader health care commitment."
UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.
These healthcare plans allow employees and employers to avoid ACA penalties but provide little coverage.
Layoffs are reported to be in the offing.
The Scottish Medicines Consortium gave a thumb's down to GSK's drug and a Boehringer COPD drug.
Britain's National Institute for Health and Care Excellence has followed through on its Kadcyla objections and has said Roche's breast cancer drug will remain off the National Health Services formulary because it is too expensive.
Medibid users auction up care in exchange for a low price.
The PBM dropped 25 more drugs from its formulary.
Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
In the latest chapter in the Sovaldi pricing saga, Senators Ron Wyden and Charles Grassley urge Gilead to clarify Sovaldi sticker shock.
UnitedHealthcare finds drug costs more than doubled.
French lawmakers have the chance to vote for off-label use of Avastin, potentially eating into the turf of higher-priced Lucentis.
Health insurers and pharmacies signed a letter asking the FDA to require biosimilars and branded biologics to share the same name.
Celebrity endorsement, co-pay cards and online edutainment are some of the ways marketers are dueling for attention in the prescription omega-3 space.
The Centers for Medicare and Medicaid Services launched a new site Monday to help patients understand how to use their health coverage.
The Italian Medicines Agency is guiding patients away from Roche's costlier AMD-indicated Lucentis.
The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.
The company signed a deal with AstraZeneca in which high-risk heart disease patients can bypass step therapy and go straight to the branded cholesterol fighter.
Patients will now be able to submit specialty prescriptions at the national chain's retail stores.
Companies including WellPoint and Highmark are deploying financial incentives for doctors to stick with recommended cancer treatments.
With pollen season approaching its peak, drugmakers are educating doctors on a new class of allergy tablets. It could be a while before they're made available for patients.
The AIDS Healthcare Foundation took out an ad in some WSJ editions saying the drug threatens to "break the bank."
The drugmaker sent Olysio + Sovaldi to regulators for an additional indication in HCV patients with liver scarring.
An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.
An analysis by Bloomberg today shows why drug pricing "keeps defying the law of gravity."
Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.
Around 25% of 18-34 year-olds have signed up for coverage. Obama's FunnyorDie appearance drives HHS traffic.
Innovator companies want the FDA to adopt separate names for biosimilars. Manufacturing changes aren't drastic enough to make it necessary, experts argued at an FTC workshop.
As the Affordable Care Act rolls out, the behaviorists at MicroMass surveyed stakeholders about the impact on industry. Jessica Brueggeman sorts out the diverse views and asks: Can healthcare reform lead pharma to operationalize its patient focus?
If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.
A study shows consumers are increasingly pleased with retail pharmacies, compared to mail order pharmacies, which are often considered a key means of driving adherence and lowering healthcare coverage costs.
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
Researchers say using additional data points offers greater insight into patient-adherence patterns.
Benefits research studies show employers expect to lay out 7% more in healthcare costs in 2014, a move that has not been accompanied by lower employee costs.
The drugstore chain says it has cut off over-prescribers of tightly controlled medications.
Data show doctors are increasingly leaning on Regeneron's Eylea over Roche's Lucentis, as the two battle for share of the wet-AMD market.
While payers' proclivity for print is well-known, many prefer to receive pharma resources digitally, research shows. Joe Dysart on tools that work for this segment.
A new survey of doctors reveals how much they know (or don't) about the looming launch of healthcare exchanges.
Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.
AstaZeneca avoids a Lipitor moment, FDA approves Novartis med for Cushing's, and Teva ventures into South Korea. Plus: a closer look at health exchanges
Price increases and belt-tightening helped prop up Eli Lilly's third quarter, but loss of formulary positioning on two key products hurt sales.
IMS has added claims data to its real-world evidence (RWE) platform, but can it satisfy industry's demand for RWE as well as a payer can?
Double Helix, a healthcare consultancy that operates across three continents, was bought by Interpublic Group's McCann Health, the network said Monday.
Pharma needs to step up its sales pitch, looking beyond a drug's top attributes, to convince payers that their drugs are worth the cost.
The drug industry is struggling with more than expiring patents and shrinking sales forces, Millennium Pharmaceuticals CEO Deborah Dunsire told industry watchers Tuesday. Rather, it's wrestling with a top-to-bottom revolution.
Responding to what it calls an "acute need" among clients for market access counsel, GfK is buying Bridgehead International, a consultancy with offices here and abroad.
AstraZeneca launched a home-delivery program for breast cancer drug Arimidex through PBM Express Scripts.
Pfizer's Lipitor had not yet gone off patent before a trio of Senate healthcare heavyweights was firing off letters to the drugmaker assailing its efforts to conserve Lipitor share through a deal with pharmaceutical benefit managers.
Pfizer said it plans not only to keep Lipitor consumer promotions running past the brand's expiry later this month. It also aims to put an OTC version of the megablockbuster on the market at some point.
A little over half of US girls ages 13 to 17 have not gotten even one dose of the HPV vaccine, and among the main reasons are poor awareness and the failure of doctors to recommend vaccination, a study shows.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.